Back to top
more

AbbVie (ABBV)

(Real Time Quote from BATS)

$193.24 USD

193.24
1,832,093

-2.21 (-1.13%)

Updated Oct 4, 2024 11:16 AM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value D Growth F Momentum D VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 18% (45 out of 251)

Industry: Large Cap Pharmaceuticals

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

AbbVie (ABBV) Gains But Lags Market: What You Should Know

by Zacks Equity Research

AbbVie (ABBV) closed at $161.97 in the latest trading session, marking a +0.4% move from the prior day.

Pfizer's (PFE) Etrasimod Meets Ulcerative Colitis Study Goals

by Zacks Equity Research

Pfizer's (PFE) late-stage candidate etrasimod achieves statistical significance in its primary endpoint of clinical remission in an ulcerative colitis study.

Benjamin Rains headshot

2 Surging Stocks to Buy to Fight Market Volatility

by Benjamin Rains

Here are a couple strong, dividend-paying stocks to consider buying amid the current economic uncertainty and market volatility.

AbbVie (ABBV) Stock Sinks As Market Gains: What You Should Know

by Zacks Equity Research

AbbVie (ABBV) closed the most recent trading day at $160.01, moving -0.02% from the previous trading session.

Amgen (AMGN) Outperforms Industry This Year So Far: What Next?

by Zacks Equity Research

Amgen's (AMGN) key drugs like Prolia, Repatha, Xgeva and biosimilars are driving sales. Amgen is also rapidly advancing its robust pipeline of early and late-stage assets.

AbbVie's (ABBV) Rinvoq Gets FDA Nod for Ulcerative Colitis

by Zacks Equity Research

FDA approves AbbVie's (ABBV) Rinvoq for the treatment of moderate-to-severe ulcerative colitis in adults. This is the fourth indication for Rinvoq in the United States.

AbbVie (ABBV) Gains But Lags Market: What You Should Know

by Zacks Equity Research

AbbVie (ABBV) closed the most recent trading day at $156.05, moving +0.11% from the previous trading session.

AbbVie (ABBV) Inks Deal to Develop COVID Antiviral Treatment

by Zacks Equity Research

AbbVie (ABBV) joins Scripps Research in the latter's SARS-CoV-2 research program to accelerate the development of new antiviral therapies for COVID-19.

AbbVie (ABBV) Inks Deal for Neuropsychiatric Conditions

by Zacks Equity Research

AbbVie (ABBV) forges an alliance with Gedeon Richter to develop novel treatments for neuropsychiatric diseases. Both collaborated in the past too on the blockbuster schizophrenia drug Vraylar.

AbbVie's (ABBV) Qulipta Meets Chronic Migraine Study Endpoints

by Zacks Equity Research

AbbVie's (ABBV) new oral anti-CGRP drug, Qulipta, demonstrates potential to reduce monthly migraine days in adults with chronic migraine in a phase III study.

Kinjel Shah headshot

Pharma Stock Roundup: PFE, SNY, ABBV's Pipeline Updates, BAYRY's Unit Sale

by Kinjel Shah

Pfizer (PFE) begins pediatric study on Paxlovid. Sanofi's (SNY) hemophilia A candidate, efanesoctocog alfa, meets the goal in a pivotal study. Bayer (BAYRY) to sell its environmental solutions business.

The Zacks Analyst Blog Highlights Microsoft, Amazon.com, NVIDIA, AbbVie and HSBC Holdings

by Zacks Equity Research

Microsoft, Amazon.com, NVIDIA, AbbVie and HSBC Holdings are included in this blog.

Genmab (GMAB), AbbVie Lymphoma Candidate Gets Orphan Drug Tag

by Zacks Equity Research

Genmab (GMAB) and AbbVie are co-developing epcoritamab as a potential treatment for non-Hodgkin's lymphoma, follicular lymphoma. The FDA grants orphan drug status for the candidate as a treatment for FL.

Kinjel Shah headshot

What's in Store for These 3 Big Pharma Outperformers in 2022?

by Kinjel Shah

J&J (JNJ), AbbVie (ABBV) and Merck (MRK) are three large drugmakers that have outperformed the industry and are good stocks to hold for the next few months and beyond.

AbbVie (ABBV) Outperforms Industry This Year So Far: What Next?

by Zacks Equity Research

AbbVie (ABBV) has several new drugs with the potential to drive revenues once Humira loses U.S. exclusivity in 2023. Its early and mid-stage pipeline has several candidates with blockbuster potential.

Sheraz Mian headshot

Top Analyst Reports for Microsoft, Amazon & NVIDIA

by Sheraz Mian

Today's Research Daily features new research reports on 16 major stocks, including Microsoft Corporation (MSFT), Amazon.com, Inc. (AMZN) and NVIDIA Corporation (NVDA).

AbbVie (ABBV) Stock Moves -0.74%: What You Should Know

by Zacks Equity Research

In the latest trading session, AbbVie (ABBV) closed at $149.45, marking a -0.74% move from the previous day.

AbbVie (ABBV) Up 6.9% Since Last Earnings Report: Can It Continue?

by Zacks Equity Research

AbbVie (ABBV) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Reata's (RETA) Q4 Earnings Miss Mark, Revenues Decline Y/Y

by Zacks Equity Research

Reata (RETA) reports a wider-than-expected loss in the fourth quarter of 2021 while revenues are slightly lower than estimates.

Kinjel Shah headshot

Pharma Stock Roundup: GSK, SNY Face Pipeline Setbacks, AZN Cancer Study Meets Goals

by Kinjel Shah

Glaxo (GSK) and Sanofi (SNY) announce pipeline setbacks. AstraZeneca's (AZN) HER2-low metastatic breast cancer study on Enhertu succeeds.

Viatris (VTRS) to Report Q4 Earnings: What's in the Cards?

by Zacks Equity Research

Viatris' (VTRS) Q4 earnings might have gained from the solid performance of Lipitor, Influvac, Viagra and EpiPen.

Ironwood (IRWD) Q4 Earnings Miss, Linzess Volume Grows

by Zacks Equity Research

Ironwood (IRWD) witnesses flat year-over-year sales growth. Its fourth-quarter earnings miss estimates. The company maintains revenue guidance for 2022. Stock declines.

Zacks Value Trader Highlights: Mastercard, Visa, Chevron and AbbVie

by Zacks Equity Research

Mastercard, Visa, Chevron and AbbVie are highlighted in this Value Trader article.

Tracey Ryniec headshot

Who's Really Making the Berkshire Hathaway Stock Trades?

by Tracey Ryniec

It used to be Warren Buffett making all the portfolio decisions, but it's pretty obvious those days are over.

Biohaven (BHVN) Migraine Drug Meets Study Goals in China

by Zacks Equity Research

Biohaven (BHVN) and partner Pfizer announce positive top-line results from a phase III study on rimegepant for the acute treatment of migraine. The study meets the co-primary endpoints.